Trials / Completed
CompletedNCT04066712
Renal PK Study of LC350189
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LC350189 in Subjects With Varying Degrees of Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LC350189 200 mg | Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7 |
Timeline
- Start date
- 2019-11-19
- Primary completion
- 2020-09-12
- Completion
- 2020-09-12
- First posted
- 2019-08-26
- Last updated
- 2020-09-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04066712. Inclusion in this directory is not an endorsement.